Alpha-4-containing nicotinic acetylcholine receptor (α4-nAChR)

Alpha-4-containing nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels primarily expressed throughout the mammalian central nervous system [1]. These receptors most commonly assemble with beta-2 subunits to form the α4β2 subtype, which represents the highest-affinity binding site for nicotine in the brain and is a central mediator of the rewarding properties of tobacco [2]. Biologically, they function as neuromodulators that regulate the release of key neurotransmitters such as dopamine, glutamate, and GABA, thereby influencing critical cognitive processes including attention, executive function, and memory [3]. Mutations in the CHRNA4 gene, which encodes the alpha-4 subunit, are directly linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), a condition characterized by brief seizures during sleep [4]. Furthermore, a significant reduction in the density of these receptors is a hallmark of neurodegenerative conditions like Alzheimer's and Parkinson's diseases, contributing to cognitive decline [5]. Pharmacologically, α4-containing nAChRs are the primary targets for smoking cessation therapies like varenicline, which acts as a partial agonist to alleviate withdrawal symptoms while blocking the reinforcing effects of nicotine [6]. They also remain a significant area of research for developing treatments for cognitive impairment, chronic pain, and mood disorders [7].

Other names

CHRNA4Neuronal acetylcholine receptor subunit alpha-4Cholinergic receptor nicotinic alpha 4 subunitAlpha-4-beta-2 nicotinic receptorNACRA4Neuronal nicotinic acetylcholine receptor alpha 4

Agonist, partial agonist, or positive allosteric modulator of the pentameric ligand-gated ion channel, facilitating the influx of sodium and calcium ions to induce neuronal depolarization.